Active substance
Pramlintide
- US FDA 1
- Safety 1
US FDA United States — FDA approvals (Drugs@FDA)
| Product | Strength | Form · route | Applicant | Status | First approved |
|---|---|---|---|---|---|
| SYMLIN | EQ 3MG BASE/5ML (EQ 600MCG BASE/ML); EQ 1.5MG BASE/1.5ML (EQ 1MG BASE/ML); EQ 2.7MG BASE/2.7ML (EQ 1MG BASE/ML) | injectable · subcutaneous | ASTRAZENECA AB | Discontinued | 16 Mar 2005 |
Safety signals and safety-related labeling changes
- US FDA 18 Dec 2019 SYMLIN — safety-related labeling change
Labeling sections changed: Use in Specific Populations
Values as published by each source: SFDA human drug list (4-2026, as published by the Council of Health Insurance; indications from the CHI Daman Drug Formulary), Drugs@FDA, EMA medicines data, Health Canada Drug Product Database (Open Government Licence – Canada), CMS NADAC, NHS Drug Tariff Part VIIIA (NHSBSA Copyright, Open Government Licence v3.0), WHO Model List of Essential Medicines (CC BY 3.0 IGO; regrouped by active substance, not created by WHO), EMA PRAC, US FDA safety-related labeling changes and MHRA Drug Safety Update (Open Government Licence v3.0). Sources and reuse. Not a substitute for the official registers or the product information.